title: Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells.
abstract: Cancer cells with active drug efflux capability are multidrug resistant and pose a significant obstacle for the efficacy of chemotherapy. Moreover, recent evidence suggests that high drug efflux cancer cells (HDECC) may be selectively enriched with stem-like cancer cells, which are believed to be the cause for tumor initiation and recurrence. There is a great need for therapeutic reagents that are capable of eliminating HDECCs. We developed an image-based high-content screening (HCS) system to specifically identify and analyze the HDECC population in lung cancer cells. Using the system, we screened 1,280 pharmacologically active compounds that identified 12 potent HDECC inhibitors. It is shown that these inhibitors are able to overcome multidrug resistance (MDR) and sensitize HDECCs to chemotherapeutic drugs, or directly reduce the tumorigenicity of lung cancer cells possibly by affecting stem-like cancer cells. The HCS system we established provides a new approach for identifying therapeutic reagents overcoming MDR. The compounds identified by the screening may potentially be used as potential adjuvant to improve the efficacy of chemotherapeutic drugs.
authors.affiliation: Medical Systems Biology Laboratory, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute, Houston, Texas 77030, USA.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Xia
authors.forename: Jian
authors.initials: J
authors.lastname: Yang
authors.forename: Fuhai
authors.initials: F
authors.lastname: Li
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Zhou
authors.forename: Yue
authors.initials: Y
authors.lastname: Dai
authors.forename: Stephen T C
authors.initials: ST
authors.lastname: Wong
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001562:Benzimidazoles / Q000737:chemistry / Q000378:metabolism; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D016572:Cyclosporine / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005434:Flow Cytometry; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D016688:Mice, Inbred NOD; D008819:Mice, Nude; D016513:Mice, SCID; D008856:Microscopy, Fluorescence; D014700:Verapamil / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D016572:Cyclosporine; D014700:Verapamil; C017807:bisbenzimide ethoxide trihydrochloride; D002945:Cisplatin